Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders.
Neuropathologically, Huntington's disease is characterized by a profound reduction in neuronal cells originating in the corpus striatum and globus pallidus. Since one of these cell types utilizes gamma-aminobutyric acid (GABA) as a neurotransmitter, it may be possible to differentially diagnose this disorder on the basis of the CSF content of this amino acid. In order to determine the validity of this hypothesis, cerebrospinal fluid GABA was analyzed, using a recently developed radioreceptor assay procedure and was found to be significantly reduced in patients diagnosed as having Huntington's disease and also lower in patients with Alzheimer's disease, though no difference was noted between Parkinson patients and control subjects. The results suggest that analysis of cerebrospinal fluid GABA may have diagnostic, and perhaps predictive, value in certain neurological disorders.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid*; D000613:Aminobutyrates / Q000134:cerebrospinal fluid*; D002648:Child; D003704:Dementia / Q000134:cerebrospinal fluid*; D006801:Humans; D006816:Huntington Disease / Q000134:cerebrospinal fluid*; D008722:Methods; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid*; D005680:gamma-Aminobutyric Acid / Q000032:analysis / Q000134:cerebrospinal fluid*
D000613:Aminobutyrates; D005680:gamma-Aminobutyric Acid